These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15829545)

  • 41. SEARCHing for JUPITER: starry-eyed optimism is not warranted.
    Wierzbicki AS
    Int J Clin Pract; 2009 May; 63(5):685-8. PubMed ID: 19392917
    [No Abstract]   [Full Text] [Related]  

  • 42. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure.
    Sola S; Mir MQ; Rajagopalan S; Helmy T; Tandon N; Khan BV
    J Card Fail; 2005 Oct; 11(8):607-12. PubMed ID: 16230264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction.
    Quinaglia e Silva JC; Munhoz DB; Morato TN; Gurgel A; Macedo AC; Sever P; Sposito AC;
    Am J Cardiol; 2009 Feb; 103(4):461-3. PubMed ID: 19195502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [C-reactive protein in coronary plaques -- prevalence with acute coronary syndrome].
    Andrié R; Maylahn M; Braun P; Lüderitz B; Bauriedel G
    Z Kardiol; 2002 Nov; 91(11):913-20. PubMed ID: 12442194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of increased temperature of the culprit lesion after recent myocardial infarction: the favorable effect of statins.
    Toutouzas K; Vaina S; Tsiamis E; Vavuranakis M; Mitropoulos J; Bosinakou E; Toutouzas P; Stefanadis C
    Am Heart J; 2004 Nov; 148(5):783-8. PubMed ID: 15523307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome.
    Fang CH; Li JJ; Hui RT
    Med Hypotheses; 2005; 64(1):192-6. PubMed ID: 15533640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 48. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials.
    Mega S; Patti G; Cannon CP; Di Sciascio G
    Crit Pathw Cardiol; 2010 Mar; 9(1):19-22. PubMed ID: 20215906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-reactive protein and cardiovascular diseases--is it ready for primetime?
    Lavie CJ; Milani RV; Verma A; O'Keefe JH
    Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In-hospital initiation of statin therapy in patients with acute coronary events.
    Fonarow GC
    Curr Atheroscler Rep; 2003 Sep; 5(5):394-402. PubMed ID: 12911850
    [No Abstract]   [Full Text] [Related]  

  • 52. Letter: viewing JUPITOR with a clear perspective.
    Kumana CR; Tse HF; Lau CP
    Evid Based Med; 2009 Jun; 14(3):70. PubMed ID: 19483020
    [No Abstract]   [Full Text] [Related]  

  • 53. More good reasons for adherence to statin therapy during acute coronary syndromes.
    Herrler T; Böhm M; Heeschen C
    Eur Heart J; 2008 Sep; 29(17):2061-3. PubMed ID: 18676969
    [No Abstract]   [Full Text] [Related]  

  • 54. C-reactive protein and vascular risk: from March to Jupiter.
    Di Angelantonio E; Cohen A
    Arch Cardiovasc Dis; 2010 Mar; 103(3):139-41. PubMed ID: 20417444
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiovascular risk estimation: important but may be inaccurate.
    Madhok V; Fahey T
    BMJ; 2006 Jun; 332(7555):1422. PubMed ID: 16737981
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of Different Statin Intensity in Chronic Kidney Disease Patients.
    Upala S; Sanguankeo A
    Am J Med; 2016 Feb; 129(2):e53. PubMed ID: 26777623
    [No Abstract]   [Full Text] [Related]  

  • 57. C-reactive protein and risk of colon cancer.
    Pasceri V; Cammarota G
    JAMA; 2004 Jun; 291(23):2818-9; author reply 2819. PubMed ID: 15199028
    [No Abstract]   [Full Text] [Related]  

  • 58. Goals of statin therapy: three viewpoints. 2002.
    Thompson GR; Packard CJ; Stone NJ
    Atheroscler Suppl; 2004 Oct; 5(3):107-14. PubMed ID: 15531283
    [No Abstract]   [Full Text] [Related]  

  • 59. [Which the number of diabetic patients type 2 necessary to treat to prevent a coronary event ?].
    Bernardo WM; Castro LC
    Rev Assoc Med Bras (1992); 2006; 52(4):196. PubMed ID: 16967130
    [No Abstract]   [Full Text] [Related]  

  • 60. Trends in High-Intensity Statin Therapy After Myocardial Infarction Among U.S. Adults, 2011-2019.
    Colantonio LD; Wang Z; Chen L; Mejia R; Bittner V; Muntner P; Rosenson RS
    J Am Coll Cardiol; 2022 May; 79(18):1870-1872. PubMed ID: 35512866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.